GlassScriptPhysician profile
Komal Talati
NPI 1164782926
$1,846.50
in general payments reported to CMS, 2019-2025
18 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.83 · 2021: $202 · 2022: $137 · 2023: $489 · 2024: $615 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $368.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $201.18 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Abiomed | $184.97 | 2023 | Impella |
| Pfizer INC. | $166.59 | 2022-2025 | |
| Glaxosmithkline, LLC. | $138.19 | 2019-2025 | Shingrix, Arexvy |
| Boston Scientific Corporation | $123.13 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.37 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $84.55 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Abbott Laboratories | $82.12 | 2022-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $80.33 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $71.84 | 2024-2025 | Inspire |
| Hologic Sales and Service, LLC | $60.52 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $48.97 | 2024 | Veozah |
| Exact Sciences Corporation | $47.29 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $33.64 | 2024 | Farxiga |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.65 | 2024 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $18.12 | 2025 | |
| Phadia US INC. | $16.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Talati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.